{"id":"https://openalex.org/W4402817775","doi":"https://doi.org/10.1158/1078-0432.c.6664583.v3","title":"Data from Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies","display_name":"Data from Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies","publication_year":2024,"publication_date":"2024-09-16","ids":{"openalex":"https://openalex.org/W4402817775","doi":"https://doi.org/10.1158/1078-0432.c.6664583.v3"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6664583.v3","doi":"https://doi.org/10.1158/1078-0432.c.6664583.v3","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6664583.v3","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6664583.v3","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1182-4908","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarina A. Piha-Paul","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9455-1660","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029723783","display_name":"Theresa Michelle Medina","orcid":"https://orcid.org/0000-0003-0579-4121","observed_orcids":["https://orcid.org/0000-0003-0579-4121"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Theresa Medina","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0579-4121","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089486616","display_name":"Claire F. Verschraegen","orcid":"https://orcid.org/0000-0001-6544-3089","observed_orcids":["https://orcid.org/0000-0001-6544-3089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claire F. Verschraegen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6544-3089","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040158883","display_name":"Mary Laura Varterasian","orcid":"https://orcid.org/0009-0007-5921-0984","observed_orcids":["https://orcid.org/0009-0007-5921-0984"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary Varterasian","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-5921-0984","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047910418","display_name":"Aoife M. Brennan","orcid":"https://orcid.org/0000-0002-3413-4723","observed_orcids":["https://orcid.org/0000-0002-3413-4723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aoife M. Brennan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3413-4723","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072429797","display_name":"Richard J. Riese","orcid":"https://orcid.org/0009-0000-3657-6229","observed_orcids":["https://orcid.org/0009-0000-3657-6229"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard J. Riese","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-3657-6229","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048162761","display_name":"Anna Sokolovska","orcid":"https://orcid.org/0000-0002-1216-696X","observed_orcids":["https://orcid.org/0000-0002-1216-696X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Sokolovska","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1216-696X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026638826","display_name":"James Fredric Strauss","orcid":"https://orcid.org/0000-0001-6414-6998","observed_orcids":["https://orcid.org/0000-0001-6414-6998"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James F. Strauss","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6414-6998","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073805604","display_name":"David L. Hava","orcid":"https://orcid.org/0000-0002-9200-1566","observed_orcids":["https://orcid.org/0000-0002-9200-1566"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David L. Hava","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9200-1566","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8123-4065","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.01140000019222498,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sting-agonist","display_name":"STING agonist","score":0.9549999833106995},{"id":"https://openalex.org/keywords/cyclic-dinucleotides","display_name":"cyclic dinucleotides","score":0.9739999771118164},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9760000109672546},{"id":"https://openalex.org/keywords/intratumoral-injection","display_name":"intratumoral injection","score":0.9340000152587891},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.6549999713897705},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9440000057220459},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7350000143051147},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.753000020980835},{"id":"https://openalex.org/keywords/interferon-stimulated-genes","display_name":"interferon-stimulated genes","score":0.9769999980926514},{"id":"https://openalex.org/keywords/innate-immunity","display_name":"innate immunity","score":0.44999998807907104},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.5649999976158142}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8270821571350098},{"id":"https://openalex.org/C2779300339","wikidata":"https://www.wikidata.org/wiki/Q7617409","display_name":"Sting","level":2,"score":0.6681813597679138},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5684480667114258},{"id":"https://openalex.org/C2778022156","wikidata":"https://www.wikidata.org/wiki/Q576145","display_name":"Strain (injury)","level":2,"score":0.4728791117668152},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4686146378517151},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41353821754455566},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.34235572814941406},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33859145641326904},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.29939377307891846},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26167166233062744},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23254919052124023},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.22073540091514587},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.10670948028564453},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.07994768023490906},{"id":"https://openalex.org/C146978453","wikidata":"https://www.wikidata.org/wiki/Q3798668","display_name":"Aerospace engineering","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6664583.v3","doi":"https://doi.org/10.1158/1078-0432.c.6664583.v3","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6664583.v3","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6664583.v3","doi":"https://doi.org/10.1158/1078-0432.c.6664583.v3","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6664583.v3","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4375956143","https://openalex.org/W3212159306","https://openalex.org/W3182668220","https://openalex.org/W2028256292"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"SYNB1891":[2,62,133,161,225],"is":[3],"a":[4,199],"live,":[5],"modified":[6],"strain":[7],"of":[8,26,61,73,79,165,176,224,239],"the":[9,70,75,111,117,138,145,156,166,193],"probiotic":[10],"E.":[11],"coli":[12],"Nissle":[13],"1917":[14],"(EcN)":[15],"engineered":[16],"to":[17,24,55,216],"produce":[18],"cyclic":[19],"dinucleotides":[20],"under":[21],"hypoxia":[22],"leading":[23],"stimulator":[25],"interferon":[27],"genes":[28,183],"(STING)-activation":[29],"in":[30,34,66,96,137,150,163,184,202,212,229],"phagocytic":[31],"antigen-presenting":[32],"cells":[33],"tumors":[35],"and":[36,43,77,90,127,169,180,189,228,234,237],"activating":[37],"complementary":[38],"innate":[39],"immune":[40],"pathways.":[41],"Patients":[42],"Methods:":[44],"This":[45],"first-in-human":[46],"study":[47],"(NCT04167137)":[48],"enrolled":[49],"participants":[50,84,92,214],"with":[51,69,105,160],"refractory":[52,215],"advanced":[53],"cancers":[54],"receive":[56],"repeat":[57],"intratumoral":[58],"(IT)":[59],"injections":[60],"either":[63],"alone":[64],"or":[65,142,149],"combination":[67,94,230],"atezolizumab,":[68],"primary":[71],"objective":[72],"evaluating":[74],"safety":[76],"tolerability":[78],"both":[80],"regimens.":[81],"Results:":[82],"Twenty-four":[83],"received":[85,93],"monotherapy":[86,227],"across":[87],"6":[88,141],"cohorts,":[89],"8":[91],"therapy":[95],"2":[97],"cohorts.":[98],"Five":[99],"cytokine":[100],"release":[101],"syndrome":[102],"events":[103,125],"occurred":[104],"monotherapy,":[106],"including":[107],"one":[108],"that":[109],"met":[110],"criteria":[112],"for":[113],"dose-limiting":[114],"toxicity":[115],"at":[116,140],"highest":[118],"dose;":[119],"no":[120,128],"other":[121],"SYNB1891-related":[122,129],"serious":[123],"adverse":[124],"occurred,":[126],"infections":[130],"were":[131],"observed.":[132,245],"was":[134,205,232,244],"not":[135],"detected":[136],"blood":[139],"24h":[143],"after":[144],"first":[146,157],"IT":[147,222],"dose":[148],"tumor":[151],"tissue":[152],"7":[153,190],"days":[154,191],"following":[155,192],"dose.":[158,196],"Treatment":[159],"resulted":[162],"activation":[164],"STING":[167,240],"pathway":[168,241],"target":[170,242],"engagement":[171,243],"as":[172,207,209,226],"assessed":[173],"by":[174],"upregulation":[175],"interferon-stimulated":[177],"genes,":[178],"chemokines/cytokines,":[179],"T-cell":[181],"response":[182],"core":[185],"biopsies":[186],"obtained":[187],"pre-dose":[188],"third":[194],"weekly":[195],"In":[197],"addition,":[198],"dose\u2011related":[200],"increase":[201],"serum":[203],"cytokines":[204],"observed,":[206],"well":[208,235],"stable":[210],"disease":[211],"4":[213],"prior":[217],"PD-1/L1":[218],"antibodies.":[219],"Conclusions:":[220],"Repeat":[221],"injection":[223],"atezolizumab":[231],"safe":[233],"tolerated":[236],"evidence":[238]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-09-25T00:00:00"}